Business Context and Reporting Period
Company: eXegenics Inc. (formerly Cytoclonal Pharmaceutics, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 2006
Business Status: The Company has no active business operations. Since 2003, it has terminated all research and development activities and eliminated scientific and administrative staff. It currently operates as a holding company with a portfolio of marketable securities, focused on redeploying residual assets and pursuing new business opportunities via a Business Opportunities Search Committee.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(648,000) | $(186,000) |
| Net Loss Attributable to Common Stockholders | $(886,000) | $(420,000) |
| Loss Per Share (Basic & Diluted) | $(0.04) | $(0.03) |
| General & Administrative Expenses | $1,117,000 | $1,438,000 |
| Interest Income | $469,000 | $190,000 |
| Cash, Cash Equivalents & Investments | $8,596,000 | $8,901,000 |
| Total Assets | $8,752,000 | $9,000,000 |
| Stockholders' Equity | $8,078,000 | $8,723,000 |
| Working Capital | $8,079,000 | $8,723,000 |
Note: The filing text does not provide specific debt figures other than accrued expenses and legal reserves. The company reported no long-term debt.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $462,000 (60%) compared to 2005. This was primarily due to the absence of a $1,064,000 gain on the sale of Javelin Pharmaceuticals, Inc. stock that occurred in 2005.
- Expense Reduction: General and administrative expenses decreased by $321,000 (22%) due to reductions in payroll, travel, insurance, and audit fees. This was partially offset by a $180,000 increase in legal expenses related to litigation reserves.
- Interest Income: Interest income increased by $279,000 (68%) due to higher interest rates on cash equivalents.
- Legal Reserves: The company increased its legal reserve for the Labidi proceeding from $250,000 in 2005 to $638,000 in 2006.
Outlook, Risks, and Unusual Items
Subsequent Event: Capital Raise
On February 9, 2007 (post-fiscal year), the Company sold 19,440,491 shares (approx. 51% of fully diluted capital) to a group of investors led by The Frost Group. The aggregate purchase price was $8,613,000, subject to adjustment based on stockholders' equity at closing. This transaction provides significant working capital for future business opportunities.
Risk Factors
- Acquisition Risk: Future success depends on identifying and integrating new business opportunities, which carries risks of failure, overpayment, and integration difficulties.
- Litigation: A jury awarded former employee Dr. Abdel Hakim Labidi $600,000 for conversion of biological materials. The final liability is estimated between $638,000 and $750,000; the company has recorded a $638,000 provision.
- Concentrated Ownership: The Frost Group owns approximately 41% of voting stock, giving them significant influence over corporate matters.
- Intellectual Property: The company has not been diligent in maintaining IP protections since terminating operations, risking loss of proprietary rights.
Investor Verification Checklist
- Capital Raise Terms: Verify the final adjusted purchase price of the February 2007 stock sale and the resulting ownership structure.
- Litigation Status: Confirm the final resolution of the Labidi proceeding and whether the $638,000 reserve is sufficient or if an appeal is filed.
- Strategic Direction: Monitor the activities of the Business Opportunities Search Committee for specific targets or merger announcements.
- Related Party Transactions: Review the sublease agreement with RFG Associates (owned by Chairman John A. Paganelli) and the compensation arrangements for interim officers.
- Preferred Stock: Note the existence of Series A convertible preferred stock with liquidation preferences and dividend rights that may impact common equity value.